Literature DB >> 6365785

Binding of cryptococcal polysaccharide to Cryptococcus neoformans.

T R Kozel, C A Hermerath.   

Abstract

Radioiodinated cryptococcal polysaccharide was used to study binding of the soluble polysaccharide to encapsulated and non-encapsulated cryptoccoci. Binding of polysaccharide to non-encapsulated cryptococci occurred rapidly over a 30-min period and was largely complete after 2 h. Bound, labeled polysaccharide was slowly eluted from Cryptococcus neoformans after the addition of unlabeled polysaccharide, indicating reversibility of binding. Non-encapsulated cryptococci bound polysaccharide in two ways. Specific binding to the yeast was saturable by ca. 82 ng of polysaccharide per 10(6) yeast cells. Nonspecific binding also occurred which was not saturable under the conditions used in our experiments. Phagocytosis of the non-encapsulated yeast strain was inhibited when the specific binding was ca. 50% saturated. Binding of polysaccharide to an encapsulated strain showed nonspecific, nonsaturable binding, but little specific binding occurred. Presumably the specific binding sites were saturated in the encapsulated strain. Polysaccharides obtained from a hypocapsular mutant (A61) and a normally encapsulated strain competed effectively with labeled serotype D polysaccharide for binding sites on non-encapsulated cryptococci and had identical phagocytosis-inhibiting properties. Similarly, polysaccharides from all four cryptococcal serotypes competed effectively with labeled serotype D polysaccharide for binding sites on the non-encapsulated strain, and all four polysaccharides inhibited phagocytosis of non-encapsulated Cryptococcus neoformans. Unmodified, de-O-acetylated, carboxyl-reduced, periodate-oxidized and reduced (polyalcohol), and Smith-degraded polysaccharides competed with labeled polysaccharide for binding sites on the cell. The unmodified, de-O-acetylated and carboxyl-reduced polysaccharides inhibited phagocytosis of non-encapsulated cells, but the polyalcohol and Smith product were unable to inhibit phagocytosis.

Entities:  

Mesh:

Substances:

Year:  1984        PMID: 6365785      PMCID: PMC264265          DOI: 10.1128/iai.43.3.879-886.1984

Source DB:  PubMed          Journal:  Infect Immun        ISSN: 0019-9567            Impact factor:   3.441


  23 in total

1.  NATURAL HOST RESISTANCE TO INFECTION WITH CRYPTOCOCCUS NEOFORMANS. III. THE EFFECT OF CRYPTOCOCCAL POLYSACCHARIDE UPON THE PHYSIOLOGY OF THE RETICULOENDOTHELIAL SYSTEM OF LABORATORY ANIMALS.

Authors:  H H GADEBUSCH; P A WARD; E P FRENKEL
Journal:  J Infect Dis       Date:  1964-02       Impact factor: 5.226

2.  Covalent attachment of proteins to polysaccharide carriers by means of benzoquinone.

Authors:  J Brandt; L O Andersson; J Porath
Journal:  Biochim Biophys Acta       Date:  1975-03-28

3.  On the structure of the capsular polysaccharide from Cryptococcus neoformans serotype C.

Authors:  A K Bhattacharjee; K J Kwon-Chung; C P Glaudemans
Journal:  Immunochemistry       Date:  1978-09

4.  Protein conjugates of polysaccharide from Cryptococcus neoforman s.

Authors:  M B Goren; G M Middlebrook
Journal:  J Immunol       Date:  1967-05       Impact factor: 5.422

5.  Stoichiometric depolymerization of polyuronides and glycosaminoglycuronans to monosaccharides following reduction of their carbodiimide-activated carboxyl groups.

Authors:  R L Taylor; H E Conrad
Journal:  Biochemistry       Date:  1972-04-11       Impact factor: 3.162

6.  Conjugation of antibodies with fluorochromes: modifications to the standard methods.

Authors:  J W Goding
Journal:  J Immunol Methods       Date:  1976       Impact factor: 2.303

7.  Genetic and phenotypic characterization of capsule mutants of Cryptococcus neoformans.

Authors:  E S Jacobson; D J Ayers; A C Harrell; C C Nicholas
Journal:  J Bacteriol       Date:  1982-06       Impact factor: 3.490

8.  Nonencapsulated Variant of Cryptococcus neoformans I. Virulence Studies and Characterization of Soluble Polysaccharide.

Authors:  T R Kozel; J Cazin
Journal:  Infect Immun       Date:  1971-02       Impact factor: 3.441

9.  Extracellular glycoprotein from virulent and avirulent Cryptococcus species.

Authors:  A Ross; I E Taylor
Journal:  Infect Immun       Date:  1981-03       Impact factor: 3.441

10.  Structural studies on the major, capsular polysaccharide from Cryptococcus bacillisporus serotype B.

Authors:  A K Bhattacharjee; K J Kwon-Chung; C P Glaudemans
Journal:  Carbohydr Res       Date:  1980-06       Impact factor: 2.104

View more
  26 in total

Review 1.  A yeast under cover: the capsule of Cryptococcus neoformans.

Authors:  Indrani Bose; Amy J Reese; Jeramia J Ory; Guilhem Janbon; Tamara L Doering
Journal:  Eukaryot Cell       Date:  2003-08

2.  Production and characterization of monoclonal antibodies specific for Cryptococcus neoformans capsular polysaccharide.

Authors:  T F Eckert; T R Kozel
Journal:  Infect Immun       Date:  1987-08       Impact factor: 3.441

3.  Effects of strain variation, serotype, and structural modification on kinetics for activation and binding of C3 to Cryptococcus neoformans.

Authors:  B J Young; T R Kozel
Journal:  Infect Immun       Date:  1993-07       Impact factor: 3.441

4.  Capsulelike surface material of Mycoplasma dispar induced by in vitro growth in culture with bovine cells is antigenically related to similar structures expressed in vivo.

Authors:  R A Almeida; R F Rosenbusch
Journal:  Infect Immun       Date:  1991-09       Impact factor: 3.441

5.  Pbx proteins in Cryptococcus neoformans cell wall remodeling and capsule assembly.

Authors:  Pardeep Kumar; Christian Heiss; Felipe H Santiago-Tirado; Ian Black; Parastoo Azadi; Tamara L Doering
Journal:  Eukaryot Cell       Date:  2014-02-28

6.  Adherence to and damage of endothelial cells by Cryptococcus neoformans in vitro: role of the capsule.

Authors:  A S Ibrahim; S G Filler; M S Alcouloumre; T R Kozel; J E Edwards; M A Ghannoum
Journal:  Infect Immun       Date:  1995-11       Impact factor: 3.441

7.  Binding of purified and radioiodinated capsular polysaccharides from Cryptococcus neoformans serotype A strains to capsule-free mutants.

Authors:  J M Small; T G Mitchell
Journal:  Infect Immun       Date:  1986-12       Impact factor: 3.441

8.  Production, characterization, and antibody specificity of a mouse monoclonal antibody reactive with Cryptococcus neoformans capsular polysaccharide.

Authors:  F Dromer; J Salamero; A Contrepois; C Carbon; P Yeni
Journal:  Infect Immun       Date:  1987-03       Impact factor: 3.441

9.  Differential stimulation of murine resident peritoneal cells by selectively opsonized encapsulated and acapsular Cryptococcus neoformans.

Authors:  S M Levitz; D J DiBenedetto
Journal:  Infect Immun       Date:  1988-10       Impact factor: 3.441

Review 10.  The capsule of the fungal pathogen Cryptococcus neoformans.

Authors:  Oscar Zaragoza; Marcio L Rodrigues; Magdia De Jesus; Susana Frases; Ekaterina Dadachova; Arturo Casadevall
Journal:  Adv Appl Microbiol       Date:  2009       Impact factor: 5.086

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.